 |
| What is Type 1 diabetes? | What is the AIDA study? | How to Join | Clinical Centers and Locations | Contact Us | Home |
Where do I go?
AIDA Participating Clinical Centers - Spain
Screening and regular visits can occur at any of our Participating Clinical Centers in Spain. For more information, contact:
Marta Hernandez Garcia
martahernandezg@gmail.comServei d´Endocrinologia i Nutricío. 5 a planta
Hospital Universitari Arnau de Vilanova
Av Alcalde Rovira Roure 80
25198 Lleida
SpainP: 0034 6191 9 6057
What is  |
The aim of the Anti-Interleukin-1 in Diabetes Action trial (AIDA) study is to test the feasibility, safety/tolerability and potential efficacy of anti-IL-1 therapy in maintaining or enhancing beta-cell function in people with new-onset Type 1 diabetes. The study employs a randomized, placebo-controlled, double-masked, parallel-group, multi-centre design. Participating clinical centres are located in 11 countries throughout Europe. |
Supported by: The active drug (Kineret®) and the non active “dummy” drug are provided by Amgen. Amgen does not provide funding for the conduct of the trial or to the researchers. The expenses of the trial are funded by grants from Juvenile Diabetes Foundation International, New York, USA, the world’s largest private diabetes fund. Funding also provided by Oresund Diabetes Academy and Steno Diabetes Center, Denmark. |
| Site Map | Contact Us | AIDA Locations | Accessibility | Contact the Web Master | AIDA Member Web Site | |
